# PTC Therapeutics, Inc. (PTCT) FY2026 Q3 Revenue by Product and Service (7 categories)

- Company: PTC Therapeutics, Inc. (PTCT)
- Statement: PTC Therapeutics, Inc. (PTCT) FY2026 Q3 P&L / Income Statement, https://plicit.ai/financials/ptct/fy2026-q3-income-statement
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001104659-26-120223
- Page: https://plicit.ai/financials/ptct/fy2026-q3-income-statement/revenue-by-product-and-service-7-categories
- Chart image: https://plicit.ai/charts/ptct-fy2026-q3-revenue-by-product-and-service-7-categories-sankey.png

## Chart details: Revenue by Product and Service (7 categories)

Income statement for 2026-07-01 through 2026-09-30. View: Product and service (7 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 357,807,000 US dollars
- **Total operating expenses**: 332,693,000 US dollars
- **Income from operations**: 25,114,000 US dollars
- **Other income (expense), net (calculated)**: negative 66,202,000 US dollars
- **(Loss) income before income tax (expense) benefit**: negative 41,088,000 US dollars
- **Income tax (expense) benefit**: 10,605,000 US dollars
- **Net (loss) income attributable to common stockholders**: negative 51,693,000 US dollars
- **Sephience**: 181,885,000 US dollars
- **Translarna**: 48,511,000 US dollars
- **Emflaza**: 25,094,000 US dollars
- **Upstaza/Kebilidi**: 14,553,000 US dollars
- **All other products**: 5,851,000 US dollars
- **Collaboration and license revenue**: 229,000 US dollars
- **Royalty revenue**: 81,684,000 US dollars
- **Total operating expenses**: 332,693,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
